ArticleFrontiers in oncology2024

Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level HER-2 expression: a case report.

Yurou Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.